Medical - Care Facilities
Compare Stocks
3 / 10Stock Comparison
SYRA vs TALK vs ACMR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Semiconductors
SYRA vs TALK vs ACMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Semiconductors |
| Market Cap | $6M | $868M | $3.92B |
| Revenue (TTM) | $8M | $229M | $901M |
| Net Income (TTM) | $-183K | $8M | $94M |
| Gross Margin | 33.2% | 43.0% | 44.4% |
| Operating Margin | -3.1% | 1.4% | 12.1% |
| Forward P/E | — | 38.2x | 29.7x |
| Total Debt | $144K | $0.00 | $303M |
| Cash & Equiv. | $2M | $37M | $766M |
SYRA vs TALK vs ACMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 23 | May 26 | Return |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | 100 | 16.7 | -83.3% |
| Talkspace, Inc. (TALK) | 100 | 265.6 | +165.6% |
| ACM Research, Inc. (ACMR) | 100 | 327.0 | +227.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SYRA vs TALK vs ACMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SYRA is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.19
- Lower volatility, beta 0.19, Low D/E 6.9%, current ratio 4.06x
- Beta 0.19, current ratio 4.06x
TALK is the clearest fit if your priority is growth exposure.
- Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
- 22.0% revenue growth vs SYRA's -9.5%
- 5.9% ROA vs SYRA's -5.4%, ROIC 3.9% vs -86.8%
ACMR has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 30.7% 10Y total return vs TALK's -48.7%
- Lower P/E (29.7x vs 38.2x)
- 10.4% margin vs SYRA's -2.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 22.0% revenue growth vs SYRA's -9.5% | |
| Value | Lower P/E (29.7x vs 38.2x) | |
| Quality / Margins | 10.4% margin vs SYRA's -2.4% | |
| Stability / Safety | Beta 0.19 vs ACMR's 3.24, lower leverage | |
| Dividends | 0.2% yield; 3-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +5.2% vs TALK's +70.4% | |
| Efficiency (ROA) | 5.9% ROA vs SYRA's -5.4%, ROIC 3.9% vs -86.8% |
SYRA vs TALK vs ACMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SYRA vs TALK vs ACMR — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACMR leads in 2 of 6 categories
SYRA leads 0 • TALK leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACMR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACMR is the larger business by revenue, generating $901M annually — 117.9x SYRA's $8M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to SYRA's -2.4%. On growth, TALK holds the edge at +29.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $8M | $229M | $901M |
| EBITDAEarnings before interest/tax | -$227,636 | $7M | $126M |
| Net IncomeAfter-tax profit | -$183,089 | $8M | $94M |
| Free Cash FlowCash after capex | $755,858 | -$2M | -$69M |
| Gross MarginGross profit ÷ Revenue | +33.2% | +43.0% | +44.4% |
| Operating MarginEBIT ÷ Revenue | -3.1% | +1.4% | +12.1% |
| Net MarginNet income ÷ Revenue | -2.4% | +3.4% | +10.4% |
| FCF MarginFCF ÷ Revenue | +9.9% | -0.9% | -7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.4% | +29.3% | +9.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +130.8% | — | -76.1% |
Valuation Metrics
ACMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 43.2x trailing earnings, ACMR trades at a 67% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, ACMR's 27.5x EV/EBITDA is more attractive than TALK's 137.8x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $6M | $868M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $4M | $830M | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -6.62x | 129.50x | 43.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 38.20x | 29.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.22x |
| EV / EBITDAEnterprise value multiple | — | 137.77x | 27.49x |
| Price / SalesMarket cap ÷ Revenue | 0.79x | 3.79x | 4.35x |
| Price / BookPrice ÷ Book value/share | 2.83x | 7.69x | 2.06x |
| Price / FCFMarket cap ÷ FCF | — | — | — |
Profitability & Efficiency
Evenly matched — TALK and ACMR each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
TALK delivers a 6.9% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-8 for SYRA. SYRA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACMR's 0.16x. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -8.1% | +6.9% | +6.1% |
| ROA (TTM)Return on assets | -5.4% | +5.9% | +3.9% |
| ROICReturn on invested capital | -86.8% | +3.9% | +7.0% |
| ROCEReturn on capital employed | -35.0% | +2.7% | +6.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 2 |
| Debt / EquityFinancial leverage | 0.07x | — | 0.16x |
| Net DebtTotal debt minus cash | -$1M | -$37M | -$463M |
| Cash & Equiv.Liquid assets | $2M | $37M | $766M |
| Total DebtShort + long-term debt | $143,787 | $0 | $303M |
| Interest CoverageEBIT ÷ Interest expense | -55.59x | — | 20.44x |
Total Returns (Dividends Reinvested)
Evenly matched — SYRA and TALK and ACMR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $1,668 for SYRA. Over the past 12 months, SYRA leads with a +517.7% total return vs TALK's +70.4%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs SYRA's -45.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +475.1% | +47.6% | +31.9% |
| 1-Year ReturnPast 12 months | +517.7% | +70.4% | +195.6% |
| 3-Year ReturnCumulative with dividends | -83.3% | +490.0% | +487.9% |
| 5-Year ReturnCumulative with dividends | -83.3% | -47.7% | +133.4% |
| 10-Year ReturnCumulative with dividends | -83.3% | -48.7% | +3065.8% |
| CAGR (3Y)Annualised 3-year return | -45.0% | +80.7% | +80.5% |
Risk & Volatility
Evenly matched — SYRA and TALK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYRA is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than ACMR's 3.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs SYRA's 71.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.19x | 0.86x | 3.24x |
| 52-Week HighHighest price in past year | $0.70 | $5.20 | $71.65 |
| 52-Week LowLowest price in past year | $0.05 | $2.22 | $19.26 |
| % of 52W HighCurrent price vs 52-week peak | +71.5% | +99.6% | +82.6% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 62.7 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 47K | 4.5M | 1.2M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TALK as "Hold", ACMR as "Buy". Consensus price targets imply 1.4% upside for TALK (target: $5) vs -32.4% for ACMR (target: $40). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy |
| Price TargetConsensus 12-month target | — | $5.25 | $40.00 |
| # AnalystsCovering analysts | — | 10 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.2% |
| Dividend StreakConsecutive years of raises | — | — | 3 |
| Dividend / ShareAnnual DPS | — | — | $0.11 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% | +0.2% |
ACMR leads in 2 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 3 categories are tied.
SYRA vs TALK vs ACMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SYRA or TALK or ACMR a better buy right now?
For growth investors, Talkspace, Inc.
(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SYRA or TALK or ACMR?
On trailing P/E, ACM Research, Inc.
(ACMR) is the cheapest at 43. 2x versus Talkspace, Inc. at 129. 5x. On forward P/E, ACM Research, Inc. is actually cheaper at 29. 7x.
03Which is the better long-term investment — SYRA or TALK or ACMR?
Over the past 5 years, ACM Research, Inc.
(ACMR) delivered a total return of +133. 4%, compared to -83. 3% for Syra Health Corp. Class A Common Stock (SYRA). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus SYRA's -83. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SYRA or TALK or ACMR?
By beta (market sensitivity over 5 years), Syra Health Corp.
Class A Common Stock (SYRA) is the lower-risk stock at 0. 19β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately 1633% more volatile than SYRA relative to the S&P 500. On balance sheet safety, Syra Health Corp. Class A Common Stock (SYRA) carries a lower debt/equity ratio of 7% versus 16% for ACM Research, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SYRA or TALK or ACMR?
By revenue growth (latest reported year), Talkspace, Inc.
(TALK) is pulling ahead at 22. 0% versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). On earnings-per-share growth, the picture is similar: Syra Health Corp. Class A Common Stock grew EPS 85. 5% year-over-year, compared to -10. 5% for ACM Research, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SYRA or TALK or ACMR?
ACM Research, Inc.
(ACMR) is the more profitable company, earning 10. 4% net margin versus -12. 4% for Syra Health Corp. Class A Common Stock — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -12. 5% for SYRA. At the gross margin level — before operating expenses — ACMR leads at 44. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SYRA or TALK or ACMR more undervalued right now?
On forward earnings alone, ACM Research, Inc.
(ACMR) trades at 29. 7x forward P/E versus 38. 2x for Talkspace, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TALK: 1. 4% to $5. 25.
08Which pays a better dividend — SYRA or TALK or ACMR?
In this comparison, ACMR (0.
2% yield) pays a dividend. SYRA, TALK do not pay a meaningful dividend and should not be held primarily for income.
09Is SYRA or TALK or ACMR better for a retirement portfolio?
For long-horizon retirement investors, Syra Health Corp.
Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYRA: -83. 3%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SYRA and TALK and ACMR?
These companies operate in different sectors (SYRA (Healthcare) and TALK (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SYRA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.